Literature DB >> 28188075

Bisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw.

Alessandro Corsi1, Claudio Ungari2, Mara Riminucci3, Alessandro Agrillo2.   

Abstract

Osteonecrosis of the jaw (ONJ) is a well known complication in patients treated with bisphosphonates (BPs) for skeletal metastasis and multiple myeloma (MM). Few oncologic patients under treatment with BPs and with ONJ and metastasis or MM at the same site of the jaw have been described. We report here on a 54-year old white female who was treated with intra-venous zoledronic acid for skeletal metastasis of breast cancer who developed ONJ. Because of a fracture at the site of ONJ, resection of the affected segment was performed. Although metastasis was not suspected by pre-operative image analysis, histological examination revealed syncronous osteonecrosis and breast cancer metastasis in the resected mandibular segment. This case highlights that, in oncologic patients treated with BPs, ONJ may hide malignancy and that histology is the unique tool by which the diagnosis of either osteonecrosis or malignancy or both can be made definitely.
Copyright © 2017 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28188075     DOI: 10.1016/j.joms.2017.01.008

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  3 in total

1.  Denosumab Related Osteonecrosis of Jaw: a Case Report.

Authors:  Marco Vinícius de Sales Lima; Jaqueline Rizzato; Daniella Varzea Gracindo Marques; Dárcio Kitakawa; Felipe da Silva Peralta; Alexandre Prado Scherma; Luis Felipe C S Carvalho
Journal:  J Oral Maxillofac Res       Date:  2018-12-30

2.  Volumetric analysis of MRONJ lesions by semiautomatic segmentation of CBCT images.

Authors:  Matthias Zirk; Johannes Buller; Joachim E Zöller; Carola Heneweer; Norbert Kübler; Max-Philipp Lentzen
Journal:  Oral Maxillofac Surg       Date:  2019-10-31

3.  Norlichexanthone purified from plant endophyte prevents postmenopausal osteoporosis by targeting ER α to inhibit RANKL signaling.

Authors:  Keqi Wang; Yongyan Chen; Shuo Gao; Maosi Wang; Mengmeng Ge; Qian Yang; Mingkai Liao; Lin Xu; Junjie Chen; Zhiping Zeng; Haifeng Chen; Xiao-Kun Zhang; Ting Lin; Hu Zhou
Journal:  Acta Pharm Sin B       Date:  2020-09-28       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.